DOI QR코드

DOI QR Code

High Expression of Bcl-2 Protein Predicts Favorable Outcome in Non-small Cell Lung Cancer: Evidence from a Systematic Review and Meta-analysis

  • Zhao, Xian-Da (Department of Pathology, School of Basic Medical Science, Wuhan University) ;
  • He, Yu-Yu (Department of Pathology, School of Basic Medical Science, Wuhan University) ;
  • Gao, Jun (Department of Molecular Pathology, Wuhan Nano Tumor Diagnosis Engineering Research Center) ;
  • Zhao, Chen (Department of Pathology, School of Basic Medical Science, Wuhan University) ;
  • Zhang, Ling-Lin (Department of Pathology, School of Basic Medical Science, Wuhan University) ;
  • Tian, Jing-Yuan (Department of Pathology, School of Basic Medical Science, Wuhan University) ;
  • Chen, Hong-Lei (Department of Pathology, School of Basic Medical Science, Wuhan University)
  • Published : 2014.11.06

Abstract

Background: The prognostic value of Bcl-2 protein expression in non-small cell lung cancer (NSCLC) is under debate. We therefore systematically reviewed the evidence for Bcl-2 protein effects on NSCLC survival to elucidate this issue. Materials and Methods: An electronic search in Pubmed and Embase complemented by manual searches in article references were conducted to identify eligible studies to evaluate the association between Bcl-2 protein expression and overall survival (OS) as well as disease free survival (DFS) of NSCLC patients. Combined hazard ratios (HRs) with corresponding 95% confidence intervals (95%CIs) were pooled using the random-effects model. Results: A total of 50 trials (including 52 cohorts) encompassing 7,765 patients were pooled in the meta-analysis regarding Bcl-2 expression and OS of NSCLC patients. High expression of Bcl-2 protein had a favorable impact (HR=0.76, 95%CI=0.67-0.86). In the group of Bcl-2 expression and DFS, 11 studies including 2,634 patients were included. The synthesized result indicated high expression of Bcl-2 protein might predict good DFS (HR=0.85, 95%CI=0.75-0.95). Conclusions: Our present meta-analysis demonstrated favorable prognostic values of Bcl-2 expression in patients with NSCLC. Further prospective trails are welcomed to validate the utility of assessing Bcl-2 in NSCLC patient management.

Keywords

Bcl-2;non-small cell lung cancer;prognosis;survival;systematic review;meta-analysis

References

  1. Abd El-Hafez A, Shawky Mohamed Ael A, Elesawy BH (2013). Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers. Asian Pac J Cancer Prev, 14, 1037-41. https://doi.org/10.7314/APJCP.2013.14.2.1037
  2. Borenstein M HL, Higgins JPT, Rothstein HR 2009. Fixed-effect versus random-effects models. introduction to meta-analysis, John Wiley & Sons, Ltd.
  3. Anagnostou VK, Lowery FJ, Zolota V, et al (2010). High expression of BCL-2 predicts favorable outcome in nonsmall cell lung cancer patients with non squamous histology. BMC Cancer, 10, 186. https://doi.org/10.1186/1471-2407-10-186
  4. Anton RC, Brown RW, Younes M, et al (1997). Absence of prognostic significance of bcl-2 immunopositivity in nonsmall cell lung cancer: analysis of 427 cases. Hum Pathol, 28, 1079-82. https://doi.org/10.1016/S0046-8177(97)90062-9
  5. Apolinario RM, van der Valk P, de Jong JS, et al (1997). Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol, 15, 2456-66.
  6. Bremnes RM, Camps C, Sirera R (2006). Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer, 51, 143-58. https://doi.org/10.1016/j.lungcan.2005.09.005
  7. Carvalho PE, Antonangelo L, Bernardi FD, et al (2000). Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol, 30, 478-86. https://doi.org/10.1093/jjco/hyd128
  8. Chipuk JE, Moldoveanu T, Llambi F, et al (2010). The BCL-2 family reunion. Mol Cell, 37, 299-310. https://doi.org/10.1016/j.molcel.2010.01.025
  9. Coate LE, John T, Tsao MS, et al (2009). Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol, 10, 1001-10. https://doi.org/10.1016/S1470-2045(09)70155-X
  10. Collins LG, Haines C, Perkel R, et al (2007). Lung cancer: diagnosis and management. Am Fam Physician, 75, 56-63.
  11. Cox G, Louise Jones J, Andi A, et al (2001). Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer, 34, 417-26. https://doi.org/10.1016/S0169-5002(01)00290-2
  12. Dosaka-Akita H, Katabami M, Hommura H, et al (1999). Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology, 56, 259-64. https://doi.org/10.1159/000011974
  13. Cox G, Walker RA, Muller S, et al (2000). Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer? Pathol Oncol Res, 6, 87-92. https://doi.org/10.1007/BF03032355
  14. D'Amico TA, Massey M, Herndon JE, 2nd, et al (1999). A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg, 117, 736-43. https://doi.org/10.1016/S0022-5223(99)70294-1
  15. Dela Cruz CS, Tanoue LT, Matthay RA (2011). Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32, 605-44. https://doi.org/10.1016/j.ccm.2011.09.001
  16. Egger M, Zellweger-Zahner T, Schneider M, et al (1997). Language bias in randomised controlled trials published in English and German. Lancet, 350, 326-9. https://doi.org/10.1016/S0140-6736(97)02419-7
  17. Fokkema E, Timens W, de Vries EG, et al (2006). Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer, 52, 241-7. https://doi.org/10.1016/j.lungcan.2005.12.009
  18. Fontanini G, Boldrini L, Vignati S, et al (1998). Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer, 34, 718-23. https://doi.org/10.1016/S0959-8049(97)10145-9
  19. Fontanini G, Vignati S, Bigini D, et al (1995). Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-smallcell lung cancer. Br J Cancer, 71, 1003-7. https://doi.org/10.1038/bjc.1995.193
  20. Fontanini G, Vignati S, Bigini D, et al (1996). Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res, 2, 1067-75.
  21. Grimminger PP, Schneider PM, Metzger R, et al (2010). The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer, 70, 82-7. https://doi.org/10.1016/j.lungcan.2009.12.013
  22. Gao Q, Yang S, Kang MQ (2012). Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Rep, 5, 1409-14.
  23. Gascoyne RD, Adomat SA, Krajewski S, et al (1997). Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, 244-51.
  24. Graziano SL, Gu L, Wang X, et al (2010). Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol, 5, 810-7. https://doi.org/10.1097/JTO.0b013e3181d89f95
  25. Grossi F, Loprevite M, Chiaramondia M, et al (2003). Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer, 39, 1242-50. https://doi.org/10.1016/S0959-8049(03)00232-6
  26. Han H, Landreneau RJ, Santucci TS, et al (2002). Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol, 33, 105-10. https://doi.org/10.1053/hupa.2002.30183
  27. Hanaoka T, Nakayama J, Haniuda M, et al (2002). Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers. Int J Clin Oncol, 7, 152-8. https://doi.org/10.1007/s101470200022
  28. Hardwick JM, Soane L (2013). Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol, 5.
  29. Higashiyama M, Doi O, Kodama K, et al (1997). bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol, 64, 48-54. https://doi.org/10.1002/(SICI)1096-9098(199701)64:1<48::AID-JSO10>3.0.CO;2-S
  30. Hwang JH, Lim SC, Kim YC, et al (2001). Apoptosis and bcl-2 expression as predictors of survival in radiation- treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 50, 13-8. https://doi.org/10.1016/S0360-3016(00)01558-3
  31. Hockenbery D, Nunez G, Milliman C, et al (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-6. https://doi.org/10.1038/348334a0
  32. Huang C, Kohno N, Inufusa H, et al (1999). Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol, 155, 955-65. https://doi.org/10.1016/S0002-9440(10)65195-4
  33. Huang CI, Neuberg D, Johnson BE, et al (2003). Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer, 98, 135-43. https://doi.org/10.1002/cncr.11461
  34. Ishida H, Irie K, Itoh T, et al (1997). The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer, 80, 1034-45. https://doi.org/10.1002/(SICI)1097-0142(19970915)80:6<1034::AID-CNCR5>3.0.CO;2-9
  35. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  36. Karpathiou G, Sivridis E, Koukourakis M, et al (2013). Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS, 121, 592-604. https://doi.org/10.1111/apm.12026
  37. Kim YC, Park KO, Kern JA, et al (1998). The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer, 22, 181-90. https://doi.org/10.1016/S0169-5002(98)00086-5
  38. Kaya V, Yildirim M, Demirpence O, et al (2013). Prognostic significance of basic laboratory methods in non- small-celllung cancer. Asian Pac J Cancer Prev, 14, 5473-6. https://doi.org/10.7314/APJCP.2013.14.9.5473
  39. Kirkin V, Joos S, Zornig M (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta, 1644, 229-49. https://doi.org/10.1016/j.bbamcr.2003.08.009
  40. Kumar VA, AK. Aster, JC 2012. Robbins basic pathology, 9th edition, Saunders.
  41. Ko E, Kim Y, Cho EY, et al (2013). Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer. Ann Surg Oncol, 20, 1005-12. https://doi.org/10.1245/s10434-012-2727-2
  42. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al (1997). Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer, 74, 565-70. https://doi.org/10.1002/(SICI)1097-0215(19971219)74:6<565::AID-IJC1>3.0.CO;2-S
  43. Kroemer G (1997). The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med, 3, 614-20. https://doi.org/10.1038/nm0697-614
  44. Kwiatkowski DJ, Harpole DH Jr., Godleski J, et al (1998). Molecular pathologic substaging in 244 stage I non-smallcell lung cancer patients: clinical implications. J Clin Oncol, 16, 2468-77.
  45. Lai RS, Wang JS, Hsu HK, et al (2002). Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn J Clin Oncol, 32, 393-7. https://doi.org/10.1093/jjco/hyf084
  46. Laudanski J, Niklinska W, Burzykowski T, et al (2001). Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. Eur Respir J, 17, 660-6. https://doi.org/10.1183/09031936.01.17406600
  47. Lee HW, Choi YW, Han JH, et al (2009). Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer, 65, 377-82. https://doi.org/10.1016/j.lungcan.2008.12.005
  48. Liu H, Zhang T, Li X, et al (2008). Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci, 99, 2185-92. https://doi.org/10.1111/j.1349-7006.2008.00922.x
  49. Mehdi SA, Tatum AH, Newman NB, et al (1999). Prognostic markers in resected stage I and II non small-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer, 1, 59-67. https://doi.org/10.3816/CLC.1999.n.004
  50. Ludovini V, Pistola L, Gregorc V, et al (2008). Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori, 94, 398-405.
  51. Ma HS H, Huang F, Li J, Cao X, Jiang W (2009). Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatinbased chemotherapy. Latin Am J Pharmacy, 28, 827-34.
  52. Mascaux C, Iannino N, Martin B, et al (2005). The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 92, 131-9. https://doi.org/10.1038/sj.bjc.6602258
  53. Mitsudomi T, Hamajima N, Ogawa M, et al (2000). Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res, 6, 4055-63.
  54. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097. https://doi.org/10.1371/journal.pmed.1000097
  55. Moldvay J, Scheid P, Wild P, et al (2000). Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res, 6, 1125-34.
  56. Nguyen VN, Mirejovsky P, Mirejovsky T, et al (2000). Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem, 102, 323-38. https://doi.org/10.1078/S0065-1281(04)70039-2
  57. O'Neill AJ, Staunton MJ, Gaffney EF (1996). Apoptosis occurs independently of bcl-2 and p53 over-expression in non-small cell lung carcinoma. Histopathology, 29, 45-50. https://doi.org/10.1046/j.1365-2559.1996.d01-478.x
  58. Pezzella F, Turley H, Kuzu I, et al (1993). bcl-2 protein in nonsmall-cell lung carcinoma. N Engl J Med, 329, 690-4. https://doi.org/10.1056/NEJM199309023291003
  59. Ohsaki Y, Toyoshima E, Fujiuchi S, et al (1996). bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res, 2, 915-20.
  60. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  61. Pastorino U, Andreola S, Tagliabue E, et al (1997). Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol, 15, 2858-65.
  62. Pierce RH, Vail ME, Ralph L, et al (2002). Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. Am J Pathol, 160, 1555-60. https://doi.org/10.1016/S0002-9440(10)61101-7
  63. Pirker R, Pereira JR, von Pawel J, et al (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol, 13, 33-42. https://doi.org/10.1016/S1470-2045(11)70318-7
  64. Poleri C, Morero JL, Nieva B, et al (2003). Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest, 123, 1858-67. https://doi.org/10.1378/chest.123.6.1858
  65. Renouf DJ, Wood-Baker R, Ionescu DN, et al (2009). BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol, 4, 486-91. https://doi.org/10.1097/JTO.0b013e318199e03a
  66. Rigau V, Molina TJ, Chaffaud C, et al (2002). Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer, 38, 169-76. https://doi.org/10.1016/S0169-5002(02)00213-1
  67. Ritter JH, Dresler CM, Wick MR (1995). Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Hum Pathol, 26, 1227-32. https://doi.org/10.1016/0046-8177(95)90198-1
  68. Shibata Y, Hidaka S, Tagawa Y, et al (2004). Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res, 24, 1925-8.
  69. Rosell R, Skrzypski M, Jassem E, et al (2007). BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One, 2, 1129. https://doi.org/10.1371/journal.pone.0001129
  70. Shea BJ, Grimshaw JM, Wells GA, et al (2007). Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 7, 10. https://doi.org/10.1186/1471-2288-7-10
  71. Shi Y, Chen L, Li J, et al (2011). Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol, 32, 381-90. https://doi.org/10.1007/s13277-010-0131-8
  72. Shim BY, Kim CH, Ahn MI, et al (2009). HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non-small cell lung cancer. Asian Pac J Clin Oncol, 5, 232-41. https://doi.org/10.1111/j.1743-7563.2009.01244.x
  73. Swinson DE, Jones JL, Cox G, et al (2004). Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer, 111, 43-50. https://doi.org/10.1002/ijc.20052
  74. Swinson DE, Jones JL, Richardson D, et al (2002). Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer, 37, 235-40. https://doi.org/10.1016/S0169-5002(02)00172-1
  75. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  76. Tomita M, Matsuzaki Y, Edagawa M, et al (2003). Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol, 29, 654-7. https://doi.org/10.1016/S0748-7983(03)00138-0
  77. Wells GA SB OCD, Peterson J, Welch V, Losos M, Tugwell P (2000). The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Online]. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  78. Williamson PR, Smith CT, Hutton JL, et al (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51. https://doi.org/10.1002/sim.1303
  79. Yaren A, Oztop I, Kargi A, et al (2006). Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract, 60, 675-82. https://doi.org/10.1111/j.1368-5031.2006.00742.x
  80. Yoo J, Jung JH, Lee MA, et al (2007). Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci, 22, 318-25. https://doi.org/10.3346/jkms.2007.22.2.318
  81. Zhang GJ, Zhang Z (2013). Effect of Bcl-2 on apoptosis and transcription factor NF-kappaB activation induced by adriamycin in bladder carcinoma BIU87 cells. Asian Pac J Cancer Prev, 14, 2387-91. https://doi.org/10.7314/APJCP.2013.14.4.2387
  82. Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 356, 800-8. https://doi.org/10.1056/NEJMoa065411
  83. Zhu ZH, Sun BY, Ma Y, et al (2009). Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol, 27, 1091-9. https://doi.org/10.1200/JCO.2008.16.6991

Cited by

  1. Over Expression of BCL2 and Low Expression of Caspase 8 Related to TRAIL Resistance in Brain Cancer Stem Cells vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4849
  2. Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling vol.14, pp.2, 2016, https://doi.org/10.3892/mmr.2016.5420
  3. Bcl-2 family in non-small cell lung cancer: its prognostic and therapeutic implications vol.67, pp.3, 2017, https://doi.org/10.1111/pin.12507